

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code : 2633

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY CONTROLLING SHAREHOLDER

This announcement is made by Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) was informed by Mr. Sum Kwong Yip, Derek (“**Mr. Sum**”) (being a controlling shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the “**Listing Rules**”) of the Company, an executive Director, chairman of the Board and chief executive officer of the Company), that between 30 June 2022 and 8 July 2022, he had through a discretionary trust established by him (as settlor) acquired a total of 8,200,000 shares of the Company (the “**Shares**”), representing approximately 0.42% of the total issued share capital of the Company as at the date of this announcement, on market at a total consideration of approximately HK\$6,220,000, representing an average price of approximately HK\$0.76 per Share (the “**Acquisitions**”). Immediately following the Acquisitions, Mr. Sum is interested in an aggregate of 1,171,988,000 Shares, representing approximately 60.59% of the total issued share capital of the Company as at the date of this announcement.

As expressed by Mr. Sum, he is confident about the future prospects and long-term development of the Group and may consider further increasing his shareholding in the Company subject to the applicable laws and regulations.

Based on the information available to the Company and to the best knowledge of the Board, the Company has continued to maintain sufficient public float of the issued Shares in compliance with the Listing Rules following the Acquisitions and as at the date of this announcement.

The shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Jacobson Pharma Corporation Limited
Yu Chun Kau
Company Secretary

Hong Kong, 11 July 2022

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.